60th Annual Meeting of the Japanese Society of Neurology

Session information

Print

Symposium

[S-07] Extending the clinical spectrum of cerebral amyloid angiopathy (CAA)

Wed. May 22, 2019 1:20 PM - 2:50 PM Room 10 (Osaka International Convention Center 12F Grande Toque)

Chair:Steven M. Greenberg(Massachusetts General Hospital, USA／Harvard Medical School, USA), Masahito Yamada(Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.

[S-07-1] Clinical spectrum of CAA-related cerebrovascular disorders

Yusuke Yakushiji, Hideo Hara (Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Japan)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.

[S-07-2] Cerebral amyloid angiopathy-related cognitive impairment and inflammation

Kenji Sakai, Masahito Yamada (Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.

[S-07-3] Extending the clinical spectrum of cerebral amyloid angiopathy (CAA)

Steven M. Greenberg1,2 (1.Massachusetts General Hospital, USA, 2.Harvard Medical School, USA)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.